Pan-ebola virus neutralizing human antibodies and methods of use therefor
US11939370B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jul 11, 2019 |
| Grant date | Mar 26, 2024 |
| Priority date | — |
| Expiry date | Aug 29, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2469/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is directed to human antibodies binding to and neutralizing ebolavirus and methods for use thereof. A further embodiment involves a monoclonal antibody, wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences. In yet another embodiment, there is provided a hybridoma or engineered cell encoding an antibody or antibody fragment. An additional embodiment comprises a vaccine formulation comprising one or more antibodies or antibody fragments characterized by clone-paired heavy and light chain CDR sequences. In still a further embodiment, there is provided a method of protecting the health of a placenta and/or fetus of a pregnant a subject infected with or at risk of infection with ebolavirus comprising delivering to said subject the antibody or antibody fragment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.